Valuation : Clene Inc.

Market Cap 47.8M 41.13M 38.73M 35.29M 66.02M 4.55B 66.28M 459M 177M 2.32B 179M 176M 7.34B P/E 2026 *
-1.45x
P/E 2027 * -2.18x
Enterprise Value 43.2M 37.17M 35M 31.89M 59.67M 4.11B 59.9M 415M 160M 2.09B 162M 159M 6.63B EV / Sales 2026 *
173x
EV / Sales 2027 * 2.13x
Free-Float
83.03%
Yield 2026 *
-
Yield 2027 * -
1 day+2.76%
1 week-10.58%
Current month-13.08%
1 month-29.55%
3 months-33.21%
6 months-32.24%
Current year-36.63%
1 week 3.48
Extreme 3.48
4
1 month 3.48
Extreme 3.48
5.11
Current year 3.48
Extreme 3.48
8.67
1 year 3.48
Extreme 3.48
13.5
3 years 2.28
Extreme 2.2801
14
5 years 2.28
Extreme 2.2801
162
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
13/8/26 Free

Founder

3,514 0.0275%
13/8/26 Free

Director

3,514 0.0275%
13/8/26 Free

Director

3,674 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
+2.76%-10.58%-43.64%-71.38% 47.8M
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.76%-5.90%+30.92%+74.62% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.31%+26.33%+11.24% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.90%-4.51%+18.60%-19.06% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.51%-5.21%+507.43% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -0.53%-2.52%+31.98%+150.46% 27.64B
Weighted average by Cap. -0.80%-1.87%+36.46%+139.02%

Financials

2026 *2027 *
Net sales 249K 215K 202K 184K 344K 23.73M 346K 2.39M 926K 12.09M 936K 916K 38.3M 23.27M 20.02M 18.85M 17.18M 32.14M 2.21B 32.27M 223M 86.35M 1.13B 87.36M 85.46M 3.57B
Net income -34.49M -29.68M -27.94M -25.46M -47.64M -3.28B -47.83M -331M -128M -1.67B -130M -127M -5.3B -31M -26.67M -25.12M -22.89M -42.82M -2.95B -42.99M -298M -115M -1.5B -116M -114M -4.76B
Net Debt -4.6M -3.96M -3.73M -3.4M -6.35M -438M -6.38M -44.17M -17.07M -223M -17.27M -16.9M -706M 1.8M 1.55M 1.46M 1.33M 2.49M 171M 2.5M 17.29M 6.68M 87.26M 6.76M 6.61M 276M
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
09/09/26 US$3.720 +2.76% 159,325
08/09/26 US$3.620 -5.97% 252,784
04/09/26 US$3.850 -3.63% 122,560
03/09/26 US$3.995 -3.97% 145,077
02/09/26 US$4.160 +1.34% 107,569
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.720USD
Average target price
32.20USD
Spread / Average Target
+765.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!